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ABSTRACT
Objectives To assess long-term golimumab efficacy/
safety in patients with active psoriatic arthritis (PsA).
Methods Adult PsA patients (≥3 swollen, ≥3 tender
joints, active psoriasis) were randomly assigned to
subcutaneous injections of placebo, golimumab 50 mg
or 100 mg every 4 weeks (q4wks) through week 20. All
patients received golimumab 50 or 100 mg beginning
week 24. Findings through 2 years are reported. Efficacy
evaluations included ≥20% improvement in American
College of Rheumatology (ACR20) response, good/
moderate response in Disease Activity Scores
incorporating 28 joints and C-reactive protein (DAS28-
CRP), ≥75% improvement in Psoriasis Area and Severity
Index (PASI75) and changes in PsA-modified Sharp/van
der Heijde scores (SHS).
Results Golimumab treatment through 2 years was
effective in maintaining clinical response (response rates:
ACR20 63%–70%, DAS28-CRP 77%–86%, PASI75
56%–72%) and inhibiting radiographic progression
(mean change in PsA-modified SHS in golimumab-
treated patients: −0.36), with no clear difference
between doses. No new safety signals were identified
through 2 years. With the study’s tuberculosis screening
and prophylactic measures, no patient developed active
tuberculosis through 2 years.
Conclusions Golimumab 50 and 100 mg for up to
2 years yielded sustained clinical and radiographic
efficacy when administered to patients with active PsA.
Increasing the golimumab dose from 50 to 100 mg
q4wks added limited benefit. Golimumab safety through
up to 2 years was consistent with other antitumour
necrosis factor α agents used to treat PsA. Treatment of
patients with latent tuberculosis identified at baseline
appeared to be effective in inhibiting the development of
active tuberculosis.
INTRODUCTION
Psoriatic arthritis (PsA), a manifestation of psoriatic
disease, involves inflammation of the peripheral/
axial joints, entheses and usually concomitant
skin/nail psoriasis. Antitumour necrosis factor
(anti-TNF) α agents are effective PsA treatments.1
Despite the abundance of long-term efficacy/safety
data for anti-TNF agents in rheumatoid arthritis
(RA), corresponding long-term data in PsA are rela-
tively sparse. Also, with the exception of the
current golimumab trial, no other trial has evalu-
ated, in a randomised fashion, two different dosing
regimens of the same anti-TNF agent in active PsA.
Golimumab is a human anti-TNF monoclonal
antibody2 administered subcutaneously every
4 weeks (q4wks) that has demonstrated efficacy in
RA2–7 and ankylosing spondylitis.8 We previously
detailed golimumab efficacy/safety through weeks
24 and 52 of the GO-REVEAL phase III, rando-
mised, double-blind, placebo-controlled trial in 405
patients with active PsA.9 10 In GO-REVEAL, sub-
cutaneous golimumab (50 or 100 mg q4 wks) sig-
nificantly improved arthritic manifestations of PsA
and associated skin disease,9 and reduced radio-
graphic progression10 versus placebo through week
24. No dose differentiation was observed, with the
exception of numerically greater responses in skin-
related endpoints with the higher golimumab
dose.9 Beginning at week 24, all patients received
golimumab 50 or 100 mg. Patients then entered the
open-label long-term study extension after week
52, in which the golimumab dose could be
increased from 50 to 100 mg q4ws. Efficacy/safety
data of long-term PsA treatment with two different
golimumab doses through 2 years are reported
herein.
PATIENTS AND METHODS
Patients
Patients were naive to anti-TNF therapy, had active
PsA (≥3 swollen, ≥3 tender joints) and had plaque
psoriasis (qualifying lesion ≥2 cm in diameter)
despite therapy with disease-modifying antirheu-
matic drugs (DMARDs) or non-steroidal anti-
inflammatory drugs (NSAIDs). Stable doses of
methotrexate (MTX), NSAIDs and corticosteroids
(prednisone ≤10 mg/day) were allowed through
week 52, after which non-biologic DMARD/
immunosuppressive, corticosteroid, NSAID and
topical therapies could be adjusted. Light therapy
was prohibited throughout the study. Patients with
latent tuberculosis identified at screening via
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purified protein derivative skin or whole blood
interferon-γ-based QuantiFERON-TB Gold testing (Cellestis,
Inc, Valencia, California, USA) could participate if treated prior
to/concurrent with study treatment. Institutional review board
or ethics committee approval and patient written informed
consent were obtained prior to study procedures.
Study design
Overall, 405 patients were randomised (1:1.3:1.3) to receive
blinded subcutaneous injections of placebo, golimumab 50 mg
or golimumab 100 mg at weeks 0, 4, 8, 12, 16 and 20, with
stratification by baseline MTX use. Golimumab ( Janssen
Research & Development, LLC, Spring House, Pennsylvania,
USA) and placebo were supplied as sterile liquid for injection.
At week 16, patients with <10% improvement in both swollen
and tender joint counts could early escape from placebo → goli-
mumab 50 mg or golimumab 50 → 100 mg; patients rando-
mised to golimumab 100 mg continued blinded 100 mg.
Starting at week 24, all patients still receiving placebo crossed
over to golimumab 50 mg. Thus, all study participants received
blinded golimumab 50 or 100 mg q4wks between week-24 and
week-52 database locks. Subsequently, patients received open-
label subcutaneous golimumab (50 or 100 mg) injections q4wks
and those receiving 50 mg could escalate the dose to 100 mg
q4wks based on investigator judgment. Patients receiving goli-
mumab 100 mg had no further dose escalation. Patients discon-
tinuing golimumab treatment were followed for approximately
4 months and contributed follow-up data to efficacy/safety ana-
lyses. Week 104 was the last evaluation for this report.
Study endpoints
The study’s co-primary endpoints, the proportion of patients
achieving ≥ 20% improvement in American College of
Rheumatology (ACR20) response criteria11 at week 149 and
change from baseline in total PsA-modified Sharp/van der
Heijde score (SHS) at week 24,10 have been reported. ACR
responses and Disease Activity Scores incorporating 28 joints
and C reactive protein (DAS28-CRP)12 13 were assessed through
week 104. Centrally digitised radiographic images obtained at
weeks 0, 52 and 104 were scored by two independent readers
in random order without knowledge of time point, patient iden-
tity or treatment using a PsA-modified SHS.14 15
The extent/severity of psoriasis were assessed by Psoriasis
Area and Severity Index (PASI) scores (range 0–72)16 among
patients with ≥ 3% of baseline body surface area (BSA) psoriasis
skin involvement. Physical function was assessed using the dis-
ability index of the Health Assessment Questionnaire
(HAQ).17 18 Dactylitis was scored in each of 20 hand/foot digits
from 0 to 3 (0=no dactylitis; 3=severe dactylitis; range 0–60).
Entheses tenderness was scored for 15 sites (0=absent;
1=present; range 0–15) using the PsA-modified (left and right
insertion of plantar fascia added) Maastricht Ankylosing
Spondylitis Enthesitis Score.19 Nail psoriasis was assessed with
the Nail Psoriasis Severity Index (NAPSI)20 for a target finger-
nail representing the worst baseline fingernail psoriasis. The
target nail was graded for nail matrix psoriasis and nail bed
psoriasis from 0 to 4 (0=no nail psoriasis; 4=nail psoriasis in
four quadrants; range 0–8). For enthesitis, dactylitis and finger-
nail psoriasis, a score ≥ 1 denoted ‘presence’.
Safety evaluations included adverse events (AEs) and routine
laboratory analyses. Patients were questioned regularly about
symptoms suggesting active TB. Antibodies to golimumab3 and
trough golimumab concentrations were determined from serum
samples collected prior to injections at selected visits.
Statistical analyses
Sample size estimation has been detailed.9 Due to
protocol-allowed changes in the golimumab regimen throughout
the study and to account for patient dropout, clinical efficacy
data were analysed using two approaches detailed below.
Descriptive statistics were employed to summarise all findings.
1. Intent-to-treat (ITT) analysis by randomised group, irre-
spective of treatment changes during the study. Missing data
for ACR, DAS28, PASI, dactylitis, enthesitis, NAPSI and
HAQ were imputed using last-observation-carried-forward
methodology; patients who discontinued treatment due to
lack of efficacy were considered non-responders for ACR/
DAS28 assessments. For radiographic data, modified ITT
analyses included patients with baseline and ≥ 1 postweek
52 SHS available. Missing week 104 PsA-modified SHSs
were imputed using last-observation-carried-forward meth-
odology between weeks 52 and 104. Intraclass correlation
coefficients were determined to assess correlation/reliability
between radiograph readers.
2. Analyses by treatment received for patients who increased
the golimumab dose from 50 → 100 mg after the week-52
database lock (per investigator judgment) and who had
≥12 weeks of follow-up.
Safety summaries included all treated patients, and individual
AEs were attributed to treatment received at event onset. The
incidences of death, serious infection, malignancy and major
adverse cardiovascular events (MACE; defined as cardiovascular
deaths or cardio/cerebrovascular serious AEs) were calculated
per 100 patient-years (/100 pt-yrs) to account for differences in
length of follow-up between treatment groups. Observed inci-
dences of malignancy were compared with those expected in
the general US population per the Surveillance, Epidemiology
and End Results (SEER) database.21 Standardised incidence
ratios were calculated as ‘observed’ (GO-REVEAL) divided by
‘expected’ (SEER database) cases of malignancy, and exact 95%
CIs were determined. Non-melanoma skin cancer (NMSC) is
not included in the SEER database and thus not included in the
comparative analyses.
RESULTS
Patient disposition and baseline characteristics
Among 555 adults screened at 58 sites,9 405 were randomised
and treated. Consent was obtained for the first patient on 12
December 2005; the last patient completed week 104 on 18
November 2008.
Patient disposition through week 249 and week 5210 have
been reported. Among 405 randomised patients, 335 (83%)
continued study treatment through week 104. The most
common reasons for study agent discontinuation were AEs
(6%–8% across randomised groups) and unsatisfactory thera-
peutic response (3%–5%) (table 1). Radiographic images and
corresponding scores were available for 397 (98%), 361 (89%)
and 331 (82%) patients at weeks 0, 52 and 104, respectively.
Baseline patient/disease characteristics were generally consist-
ent among randomised treatment groups (table 2), with the
exception of higher baseline SHS in patients receiving MTX at
baseline. Despite the investigator’s ability to adjust concomitant
non-biologic DMARD/immunosuppressive, corticosteroid and/
or NSAID treatment starting at week 52, the proportions of
patients taking these medications and the mean doses at week
104 were generally similar or slightly lower versus baseline
(tables 2 and 3).
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Table 2 Baseline patient characteristics and concomitant medication use
Golimumab
Placebo 50 mg 100 mg
No. of patients randomised 113 146 146
Male 69 (61%) 89 (61%) 86 (59%)
Caucasian 110 (97%) 141 (97%) 142 (97%)
Age (years) 47.0±10.6 45.7±10.7 48.2±10.9
PsA duration (years) 7.6±7.9 7.2±6.8 7.7±7.8
Number of swollen joints (0–66) 13.4±9.8 14.1±11.4 12.0±8.5
Number of tender joints (0–68) 21.9±14.7 24.0±17.1 22.5±15.7
CRP (mg/dl) 1.3±1.6 1.3±1.6 1.4±1.8
DAS28 using CRP 4.9±1.0 5.0±1.1 4.9±1.1
PsA-modified SHS of hands and feet (0–528) 16.3±26.7 23.0±35.3 20.4±35.7
Patients receiving MTX 24.4±35.4 28.9±42.7 28.9±42.6
Patients not receiving MTX 12.0±15.3 19.1±26.1 18.1±25.9
Patients with dactylitis 38 (34%) 50 (34%) 49 (34%)
Dactylitis score (1–60) 3.1±2.1 6.3±6.1 5.4±6.7
Patients with enthesitis 88 (78%) 109 (75%) 115 (79%)
PsA-modified MASES score (1–15) 5.0±4.1 5.7±4.0 6.1±4.1
Patients with ≥3% BSA 79 (70%) 109 (75%) 108 (74%)
BSA (%) 14.7±15.7 16.2±17.7 17.7±18.3
PASI score (0–72) 8.4±7.4 9.8±8.6 11.1±9.5
HAQ score (0–3) 1.0±0.5 1.0±0.6 1.1±0.6
Patients with fingernail involvement 83 (74%) 95 (65%) 109 (75%)
NAPSI score (1–8) of target fingernail 4.4±2.2 4.7±2.2 4.6±2.1
Patients receiving MTX 54 (48%) 71 (49%) 69 (47%)
Dose (mg/week) 15.0±4.4 14.8±4.7 15.5±5.1
Patients receiving oral corticosteroids 19 (17%) 19 (13%) 27 (19%)
Dose (mg/day) 5.8±1.7 7.6±2.4 6.0±2.2
Patients receiving NSAIDs 88 (78%) 110 (75%) 110 (75%)
Values are mean±SD or n (%) unless otherwise noted.
BSA, body surface area; CRP, C reactive protein; DAS28, Disease Activity Score employing 28-joint count; HAQ, Health Assessment
Questionnaire; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index;
NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SHS, Sharp/van der
Heijde score.
Table 1 Patient disposition through week 104
Placebo Golimumab 50 mg Golimumab 100 mg
Randomised patients 113 146 146
Treated patients 113 146 146
Treatment received*
Golimumab 50 mg 102 (90.3%) 146 (100.0%) 0 (0.0%)
Placebo → golimumab 50 mg in early escape (weeks 16–104) 51 (50.0%) 0 (0.0%) 0 (0.0%)
Dose escalated to 100 mg (weeks 52–104) 13/51 0 0
Placebo → golimumab 50 mg in crossover (weeks 24–104) 51 (50.0%) 0 (0.0%) 0 (0.0%)
Dose escalated to 100 mg (weeks 52–104) 14/51 0 0
Golimumab 50 mg only 0 (0.0%) 118 (80.8%) 0 (0.0%)
Dose escalated to 100 mg (weeks 52–104) 0 28/118 0
Golimumab 50 mg →100 mg in early escape (weeks 16–104) 0 (0.0%) 28 (19.2%) 0 (0.0%)
Golimumab 100 mg 25 (22.1%) 56 (38.4%) 146 (100.0%)
Patients who discontinued study agent 25 (22.1%) 28 (19.2%) 17 (11.6%)
Initiated protocol-prohibited medication 0 (0.0%) 0 (0.0%) 0 (0.0%)
Adverse event 9 (8.0%) 8 (5.5%) 10 (6.8%)
Worsening of psoriatic arthritis 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unsatisfactory therapeutic effect 6 (5.3%) 5 (3.4%) 4 (2.7%)
Lost to follow-up 1 (0.9%) 4 (2.7%) 1 (0.7%)
Death 0 (0.0%) 1 (0.7%) 0 (0.0%)
Other 9 (8.0%) 10 (6.8%) 2 (1.4%)
*Patients randomised to placebo who did not early escape and discontinued study agent prior to week 24 are excluded.
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Table 3 Summary of efficacy and concomitant medication use at week 104 by randomised treatment group
Golimumab
Placebo* 50 mg† 100 mg‡
No. of patients randomised 113 146 146
RADIOGRAPHIC RESPONSES
Change in PsA-modified SHS§
Total score, N= 87 117 128
0.08±3.19 −0.39±2.04 −0.32±1.87
0.0 (−0.5, 0.5) 0.0 (−0.9, 0.0) 0.0 (−0.5, 0.0)
MTX use at baseline, N= 51 61 63
−0.24±2.09 −0.78±1.76 −0.65±2.15
0.0 (−0.5, 0.5) 0.0 (−1.0, 0.0) 0.0 (−1.0, 0.0)
No MTX use at baseline, N= 36 56 65
0.53±4.30 0.03±2.25 0.00±1.51
0.0 (−0.5, 0.3) 0.0 (−0.5, 0.5) 0.0 (0.0, 0.0)
Erosion score, N= 85 114 125
0.06±2.89 −0.39±1.49 −0.38±1.33
0.0 (−0.5, 0.0) 0.0 (−0.5, 0.0) 0.0 (−0.5, 0.0)
Joint space narrowing score, N= 85 114 125
0.02±0.60 0.01±0.84 −0.02±0.73
0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Changes in PsA-modified SHS from weeks 52 to 104, N= 87 116 127
−0.03±1.59 −0.10±1.00 0.02±0.71
0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Pts with change in PsA-modified SHS>SDC, N= 85 114 125
7 (8.2%) 5 (4.4%) 5 (4.0%)
Pts with change in total PsA-modified SHS≤0, N= 85 114 125
62 (72.9%) 88 (77.2%) 96 (76.8%)
CLINICAL RESPONSES
DAS28-CRP score 3.1±1.3 2.9±1.3 2.8±1.2
2.9 (2.0, 4.1) 2.6 (1.8, 3.7) 2.6 (1.7, 3.6)
DAS28-CRP responders (good or moderate), n (%) 87 (77.0%) 126 (86.3%) 125 (85.6%)
Enthesitis—PsA-modified MASES score,¶ N = 88 109 115
Score 2.9±3.8 2.4±3.6 2.6±3.9
1.0 (0.0, 5.0) 0.0 (0.0, 4.0) 1.0 (0.0, 4.0)
% Improvement from baseline 40.4±92.7% 59.5±70.0% 56.0±72.7%
64.0% 100.0% 90.9%
(7.9, 100.0)% (33.3, 100.0)% (42.9, 100.0)%
Dactylitis,** N= 38 50 49
Score 1.1±2.4 1.3±4.1 0.8±2.4
0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
% Improvement from baseline 67.4±69.3% 83.0±36.4% 85.3±38.5%
100.0% 100.0% 100.0%
(75.0, 100.0)% (100.0, 100.0) % (100.0, 100.0) %
HAQ
Score 0.7±0.7 0.6±0.6 0.6±0.6
0.5 (0.0, 1.0) 0.4 (0.0, 1.0) 0.5 (0.0, 1.0)
Pts with HAQ improvement ≥ 0.3 units 61 (54.0%) 77 (52.7%) 86 (58.9%)
PASI,†† N= 79 109 108
Score 3.0±5.8 2.5±4.1 1.9±2.7
1.2 (0.1, 2.8) 1.4 (0.0, 2.8) 1.1 (0.0, 2.6)
NAPSI,‡‡ N= 83 95 109
Score 1.5±1.9 2.0±2.6 1.3±1.9
1.0 (0.0, 3.0) 1.0 (0.0, 4.0) 0.0 (0.0, 2.0)
% Improvement from baseline 61.8±48.8% 60.6±48.3% 69.7±50.1%
80.0% 75.0% 100.0%
(33.3,100.0)% (33.3,100.0)% (50.0,100.0)%
Concomitant medication use at week 104
MTX 53 (46.9%) 63 (43.2%) 68 (46.6%)
Dose (mg/week) 14.2±4.9 13.7±4.6 14.9±5.0
Oral corticosteroids 17 (15.0%) 18 (12.3%) 24 (16.4%)
Dose (mg/day) 5.8±1.7 7.1±3.0 6.6±4.3
NSAIDs 80 (70.8%) 98 (67.1%) 102 (69.9%)
Improvement from prior to → 12 weeks after dose escalation Patients with dose escalation and ≥12 weeks of follow-up (n=33)
DAS28-CRP
Continued
1780 Kavanaugh A, et al. Ann Rheum Dis 2013;72:1777–1785. doi:10.1136/annrheumdis-2012-202035
Clinical and epidemiological research
 group.bmj.com on November 29, 2013 - Published by ard.bmj.comDownloaded from 
Efficacy results based on ITT analyses (see ‘Statistical
analyses’)
ACR and DAS28-CRP responses
Among randomised patients, week 104 response rates were
63%–70%, 46%–51% and 29%–36% for ACR20, ACR50 and
ACR70, respectively (figure 1A). ACR responses were similar
irrespective of baseline MTX use (figure 1B,C). Also, 77%–86%
of randomised patients achieved DAS28-CRP responses of
good/moderate; mean DAS28-CRP scores at week 104 were
2.8–3.1 (table 3).
Dactylitis and enthesitis
Through week 104, mean per cent improvements in dactylitis score
were 67%–85% in patients with baseline dactylitis and in the
PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score
were 40%–60% among patients with baseline enthesitis (table 3).
Figure 1 The proportions of patients achieving clinical improvement, defined by at least 20%, 50% and/or 70% improvement in the American
College of Rheumatology (ACR20, ACR50, and ACR70, respectively) response criteria ((A) all patients, (B) patients with methotrexate (MTX) use at
baseline, (C) patients with no MTX use at baseline) or at least 50%, 75% and/or 90% improvement in the Psoriasis Area and Severity Index
(PASI50, PASI75 and PASI90, respectively) response criteria among randomised patients with baseline psoriasis involving ≥3% body surface area
((D) all patients, (E) patients with MTX use at baseline, (F) patients with no MTX use at baseline). Patients were assessed according to randomised
treatment group using an intent-to-treat analysis and missing data imputation rules were applied. Placebo patients include all patients randomised
to the placebo arm, including those who early escaped at week 16 or crossed over at week 24 to receive golimumab 50 mg or dose escalated after
the week-52 database lock to receive golimumab 100 mg. Patients in the golimumab 50-mg group include all patients who were randomised to the
golimumab 50-mg arm including those patients who early escaped at week 16 or dose escalated after the week-52 database lock to receive
golimumab 100 mg. Patients in the golimumab 100-mg group include all patients randomised to the golimumab 100-mg arm; these patients had
no change in study treatment through week 104.
Table 3 Continued
Golimumab
Placebo* 50 mg† 100 mg‡
Score (12 weeks after dose escalation) 3.0±1.0 / 3.1 (2.3, 3.8)
% Improvement 2.4±37.2% /6.3 (−12.2, 28.0)%
PASI††
Score (12 weeks after dose escalation) 1.9±3.0 / 0.4 (0.0, 2.8)
% Improvement 32.5±38.8% / 22.2 (0.0, 70.0)%
Data shown are mean±SD and median (IQR) or number (%) of patients at week 104, unless otherwise specified.
*Includes patients who early escaped at week 16 or crossed over at week 24 to receive golimumab 50 mg with the possibility to dose escalate after the week-52 database lock to
receive golimumab 100 mg.
†Includes patients who early escaped at week 16 or dose escalated after the week-52 database lock to receive golimumab 100 mg.
‡Includes patients randomised to receive golimumab 100 mg at week 0. Patients in this group did not change study treatment.
§Includes patients who had baseline and at least one total PsA-modified SHS after week 52. Data derived from Reading Session 2.
¶Among patients with enthesitis at baseline.
**Among patients with dactylitis at baseline.
††Among patients with ≥3% BSA involvement at baseline.
‡‡Among patients with nail involvement at baseline.
BSA, body surface area; DAS28-CRP, Disease Activity Score employing 28-joint count and C reactive protein; HAQ, Health Assessment Questionnaire; MASES, Maastricht Ankylosing
Spondylitis Enthesitis Score; MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA,
psoriatic arthritis; SDC, smallest detectable change (=1.79); SHS, Sharp/van der Heijde score.
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Skin and nail responses
PASI75 response (figure 1D) was achieved at week 104 in 56%–
72% of randomised patients with baseline psoriasis involving
≥3% BSA. PASI responses were similar irrespective of baseline
MTX use (figure 1E,F). Mean per cent improvements in NAPSI
scores ranged from 61% to 70% among patients with baseline
fingernail psoriasis (table 3).
Physical function
Clinically meaningful improvements in physical function (HAQ
decrease ≥ 0.3)22 were observed at week 104 for 53%–59% of
randomised patients. Mean week 104 HAQ scores were 0.6–0.7
(table 3).
Radiographic response
The two readers demonstrated good agreement in radiographic
image scoring, with intraclass correlation coefficients of 0.96 at
baseline, week 52 and week 104. At week 104, mean±SD
changes from baseline in PsA-modified SHS were 0.08±3.19, –
0.39±2.04 and −0.32±1.87 in the placebo, 50 mg and 100 mg
groups, respectively (figure 2A). Patients receiving MTX at base-
line demonstrated numerically less progression at week 104
than patients not receiving MTX (table 3, figure 2). Mean
changes in SHS erosion and joint-space-narrowing subscores are
presented in table 3.
Efficacy results for patients who received a golimumab dose
increase (50 → 100 mg) (see ‘Statistical analyses’)
In all, 33 patients receiving golimumab 50 mg q4wks had their
dose escalated based on the investigator’s judgment to 100 mg
q4wks after the week-52 database lock and had ≥12 weeks of
follow-up postescalation. These patients generally had low
disease activity prior to dose escalation, with a median (mean)
Figure 2 Psoriatic arthritis
(PsA)-modified Sharp/van der Heijde
score (SHS). (A–C) Changes from
baseline in the total PsA-modified SHS
at week 104 by randomised treatment
group and baseline methotrexate
(MTX) use. (A) All patients, (B)
patients receiving MTX at baseline and
(C) patients not receiving MTX at
baseline. Figures include patients who
had a total modified SHS at baseline
and after week 52. Means are
represented by solid lines, medians by
dotted lines and IQRs by bars. Missing
data rules were applied. (D–F)
Empirical cumulative distribution
function of change from baseline in
total PsA-modified SHS at week 104
by randomised group and baseline
MTX use. (D) All patients, (E) patients
receiving MTX at baseline and (F)
patients not receiving MTX at baseline.
The cumulative distribution function
plots include patients who had scores
at baseline and after week 52. No
missing data imputation was applied
(ie, plots exclude two, three and three
patients in the placebo, golimumab
50-mg and golimumab 100-mg
groups, respectively, who were
included in the analysis of change
from baseline to week 104 in figure
2A–C). All panels: placebo patients
include all patients randomised to the
placebo arm, including those who
early escaped at week 16 or crossed
over at week 24 to receive golimumab
50 mg or dose escalated after the
week-52 database lock to receive
golimumab 100 mg. Patients in the
golimumab 50-mg group include all
patients who were randomised to the
golimumab 50-mg arm including those
who early escaped at week 16 or dose
escalated after the week-52 database
lock to receive golimumab 100 mg.
Patients in the golimumab 100-mg
group include all patients randomised
to the golimumab 100-mg arm; these
patients had no change in study
treatment through week 104.
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DAS28-CRP score of 3.4 (3.3) and PASI score of 1.5 (3.2).
Dose escalation provided limited benefit at 12 weeks following
initiation of the higher golimumab dose, with more improve-
ment observed in skin disease than arthritis (table 3).
Golimumab pharmacokinetics and antibodies to golimumab
Dose-proportional pharmacokinetics was generally observed
through 2 years of treatment. Median serum golimumab con-
centrations were maintained over time and corresponded with
the observed sustained clinical efficacy. Consistent with findings
through week 249 and week 52,10 few patients developed anti-
bodies to golimumab through week 104 (5.4% (21/388) among
patients with ≥ 1 sample after the first administration of study
agent). The development of antibodies to golimumab appeared
to be less common in patients receiving (1.6% (3/191)) versus
not receiving (9.1% (18/197)) baseline MTX and in patients
who received golimumab 50 mg only (7/162, 4.3%) or 100 mg
only (8/145, 5.5%) versus patients who increased the golimu-
mab dose from 50 to 100 mg (6/81, 7.4%).
Safety results
AEs through week 104
Per protocol, no patient received placebo beyond week 24. The
most commonly reported AEs in golimumab-treated patients
were upper respiratory tract infection (23% of patients) and
nasopharyngitis (16%). Infections occurred in 248 (63%)
golimumab-treated patients. In general, no differences in the
types of AEs were observed between golimumab 50 and 100 mg
(table 4).
Overall, 23 (6%) golimumab-treated patients discontinued
study agent because of an AE, including 11 (4%) and 12 (5%)
patients receiving golimumab 50 and 100 mg, respectively (table
4). AEs leading to discontinuation observed in > 1 patient
overall included increased alanine aminotransferase (4–50 mg,
Table 4 Summary of safety through week 104
Golimumab*
50 mg 100 mg Combined
No. treated pts† 248 227 394
Average duration of follow-up (weeks) 75.1 76.3 91.2
Average number of administrations 18.2 18.5 22.1
Pts with ≥1 adverse event 194 (78.2%) 161 (70.9%) 331 (84.0%)
Pts with ≥1 serious adverse event 16 (6.5%) 18 (7.9%) 34 (8.6%)
Pts who discontinued study agent because of an adverse event 11 (4.4%) 12 (5.3%) 23 (5.8%)
Pts with ≥1 infection 136 (54.8%) 115 (50.7%) 248 (62.9%)
All malignancies
Pts with event 3 5 8
Incidence/100 pt-yrs (95% CI) 0.84 (0.17 to 2.45) 1.51 (0.49 to 3.52) 1.16 (0.50 to 2.29)
SIR (95% CI) relative to SEER (excluding NMSC) 1.22 (0.15 to 4.41) 1.10 (0.13 to 3.99) 1.16 (0.32 to 2.97)
Type of malignancies
Pts with lymphoma 0 0 0
Incidence/100 pt-yrs (95% CI) 0.00 (0.00 to 0.84) 0.00 (0.00 to 0.90) 0.00 (0.00 to 0.43)
SIR (95% CI) relative to SEER 0.00 (0.00 to 35.70) 0.00 (0.00 to 33.76) 0.00 (0.00 to 17.35)
Pts with NMSC 1 3 4
Incidence/100 pt-yrs (95% CI) 0.28 (0.01 to 1.56) 0.90 (0.19 to 2.64) 0.58 (0.16 to 1.48)
Pts with other malignancies (excluding NMSC) 2 2 4
Incidence/100 pt-yrs (95% CI) 0.56 (0.07 to 2.02) 0.60 (0.07 to 2.17) 0.58 (0.16 to 1.48)
SIR (95% CI) relative to SEER 1.28 (0.16 to 4.63) 1.16 (0.14 to 4.18) 1.22 (0.33 to 3.12)
Golimumab injection-site reaction
Pts 15 (6.0%) 16 (7.0%) 31 (7.9%)
Injections 38/4524 (0.8%) 35/4196 (0.8%) 73/8720 (0.8%)
Pts with >1 markedly abnormal postbaseline value, N= 248 208 394
Haematology parameter‡
Decreased neutrophil count 0 (0.0%) 2 (1.0%) 2 (0.5%)
Decreased lymphocyte count 2 (0.8%) 1 (0.5%) 3 (0.8%)
Elevated eosinophil count 1 (0.4%) 3 (1.4%) 4 (1.0%)
Clinical chemistry parameter§ (N=207)
Elevated ALT 3 (1.2%) 2 (1.0%) 5 (1.3%)
Elevated AST 2 (0.8%) 1 (0.5%) 3 (0.8%)
Elevated total bilirubin 2 (0.8%) 4 (1.9%) 6 (1.5%)
Elevated glucose 1 (0.4%) 2 (1.0%) 3 (0.8%)
Data shown are number (%) of patients at week 104, unless otherwise specified.
*With or without methotrexate.
†Patients may appear in more than one column.
‡Markedly abnormal neutrophil count and lymphocyte count decreases defined as ≥ 33% decrease and value <1.0×103/ml; markedly abnormal eosinophil count increase defined as ≥
100% increase and value >0.8×103/ml.
§Markedly elevated total bilirubin value defined as ≥100% increase and value >1.5 mg/dl, markedly elevated ALT/AST value defined as ≥100% increase and value >150 IU/l, markedly
elevated glucose value defined as ≥100% and value >250 mg/dl.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; NMSC, non-melanoma skin cancer; pt, patients; pt-yrs, patient-years; SEER, Surveillance,
Epidemiology and End Results database; SIR, standardised incidence ratio (observed/expected based on the SEER database (2004), adjusted for age, gender and race).
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1–100 mg patients), increased aspartate aminotransferase (3–
50 mg, 1–100 mg patients) and basal cell carcinoma (BCC, 1–
50 mg, 3–100 mg patients).
Serious AEs were reported for 16 (6.5%) and 18 (8%) patients
receiving golimumab 50 and 100 mg, respectively (table 4). Six
patients had serious infections: two had an abscess and one had
superficial thrombophlebitis while receiving golimumab 50 mg
and one patient each had acute cholecystitis/sepsis, cellulitis and
histoplasmosis while receiving golimumab 100 mg. The patient
with histoplasmosis resided in an endemic area and was success-
fully treated with voriconazole. When assessed according to
patient-years of follow-up, no increase in the incidence of serious
infection was observed for golimumab- (0.84 (95% CI 0.17 to
2.45) for 50 mg; 1.20 (95% CI 0.33 to 3.07) for 100 mg) versus
placebo- (9.41 (95% CI 2.56 to 24.08)) treated patients, although
the analyses are limited by a relatively short duration of placebo
treatment and small number of patients. No patient developed
active tuberculosis through week 104, including 44 patients
requiring tuberculosis prophylaxis following detection of latent
disease at screening. Through week 104, one patient received
treatment for latent tuberculosis newly diagnosed at week 36.
Four MACE cases were observed through week 104: acute
myocardial infarction (100 mg), congestive cardiac failure
(100 mg), myocardial infarction (50 mg) and myocardial ischae-
mia (placebo). The MACE incidence/100 pt-yrs indicated no
increase with golimumab (0.28 (95% CI 0.01 to 1.56) for
50 mg; 0.60 (0.07 to 2.17) for 100 mg) versus placebo (2.35
(95% CI 0.06 to 13.10)) treatment.
Two golimumab 50 mg randomised patients died (one climb-
ing accident, one small cell lung cancer) through week 52.10 No
deaths occurred from weeks 52 to 104. When assessed by
patient-years of follow-up, no increase in the incidence of death
was observed for golimumab- (0.56 (95% CI 0.07 to 2.02) for
50 mg; 0.00 (95% CI 0.00 to 0.90) for 100 mg) versus placebo-
(0.00 (95% CI 0.00 to 7.04)) treated patients.
Eight malignancies were documented through week 104,
including colon cancer (placebo → golimumab 50 mg), prostate
cancer (100 mg), two squamous cell lung cancers (1–50 mg,
1–100 mg) and four BCCs (1–50 mg, 3–100 mg). When assessed
by patient-years of follow-up, the incidence of malignancies for
golimumab-treated patients was numerically higher (see table 4)
compared with patients receiving placebo (0.00/100 pt-yrs (95%
CI 0.00 to 7.04)).
In an analysis comparing incidences of all malignancies
(excluding NMSC) observed in GO-REVEAL and expected
rates in the general US population, 95% CIs for the standardised
incidence ratios contained 1 for all treatment groups (0.00
(95% CI 0.00 to 14.57) for placebo; 1.22 (95% CI 0.15 to
4.41) for 50 mg; 1.10 (95% CI 0.13 to 3.99) for 100 mg).
Together, week 104 findings suggest no increase in malignancies
among golimumab-treated patients, although analyses are
limited by small sample size and short period of placebo
follow-up.
Injection-site reactions, most commonly mild injection-site
erythema, occurred in 31 (8%) patients through week 104
(table 4). No injection-site reaction was severe, serious or
resulted in treatment discontinuation. No patient experienced
anaphylactic or serum sickness-like reactions.
Laboratory values
Consistent with clinical laboratory findings reported through
week 52,10 few golimumab-treated patients had > 1 markedly
abnormal postbaseline haematology or chemistry laboratory
value through week 104 (table 4).
DISCUSSION
We previously reported on the efficacy and safety of the human
monoclonal anti-TNF agent golimumab, administered subcutane-
ously q4wks at doses of 50 or 100 mg, in patients with active
PsA.9 10 Briefly, when compared with the control arm, golimumab-
treated patients displayed significant and/or clinically meaningful
improvements in all aspects of PsA, including peripheral arthritis,
enthesitis, dactylitis and skin/nail psoriasis. In addition, consistent
with other anti-TNF agents, golimumab treatment inhibited pro-
gression of radiographic damage in the hands and feet of patients
with active PsA. The safety profile of golimumab was also consist-
ent with other anti-TNF agents used to treat Patients with PsA.
Despite the lack of a control arm in the long-term study exten-
sion, findings through week 104 support the benefit of golimumab
in maintaining clinical and radiographic responses observed in
PsA. Patient attrition for all golimumab-treated patients was 17%
through week 104, including 7% and 4% of patients discontinuing
due to AEs and lack of efficacy, respectively. When analysed using
ITT methodology with imputation of missing data, week 104
response rates were 67%–70% for ACR20, 47%–51% for ACR50
and 63%–72% for PASI75 (among patients with ≥3% of BSA
psoriasis involvement). Similar clinical responses were observed
among patients receiving and not receiving MTX at baseline.
Improvements were also observed in dactylitis, enthesitis and
nails psoriasis, and golimumab-treated patients also continued to
exhibit inhibition of structural damage, with a mean change in SHS
from baseline to week 104 of −0.32 to −0.39 in patients rando-
mised to golimumab. No clear differences between golimumab 50
and 100 mg were observed in long-term efficacy findings. In
general, patients receiving MTX at baseline had smaller changes
from baseline to week 104 in total SHS compared with patients not
receiving MTX, despite having more radiographic damage at base-
line. Among patients who crossed over from placebo→ golimumab
50 mg, slightly fewer patients achieved some of the clinical
responses at week 104 versus patients receiving golimumab from
week 0; these patients also appeared to have more radiographic pro-
gression through week 104, This is consistent with observations
through week 52,10 suggesting a delay in golimumab treatment may
yield differences in disease activity persisting up to 2 years in favour
of patients starting treatment earlier, although it is not known if
those differences are clinically meaningful for treated patients.
The exact benefit of dose increase from golimumab 50 mg
q4wks → 100 mg q4wks is difficult to discern given the lack of an
adequate control arm. In general, there was no clear benefit of dose
increase, with the exception of possible further improvement in the
PASI score (median of 22% improvement in PASI score 12 weeks
after dose escalation compared with before dose escalation).
Safety events observed through week 104 in these patients receiv-
ing golimumab after week 24 were consistent with safety reported
through study weeks 24 and 52, with the exception of a case of
histoplasmosis occurring after week 52 (golimumab 100 mg).
Overall, 84% of golimumab-treated patients had ≥1 AE, with no
clear difference between golimumab 50 and 100 mg in the fre-
quency of AEs. Importantly, no patient developed active tuberculosis
through 2 years, indicating that initiating treatment of latent tuber-
culosis prior to or concurrent with golimumab and close supervision
of such patients during the treatment appear to be effective in
decreasing the risk of developing active tuberculosis. Eight malignan-
cies were observed in golimumab-treated patients, including four
with BCC. The incidence of malignancies other than BCC was not
different from the general US population per the SEER database.21
The observed incidence of NMSC through 2 years in golimumab-
treated patients (four patients with BCC and baseline psoriasis) was
within ranges observed in adalimumab psoriasis clinical trials.23
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A challenge of conducting clinical trials in patients with chronic
arthropathies (eg, PsA, RA) is the ethical concern of treating
patients with placebo or suboptimal treatment for ≥3–6 months,
yielding a paucity of long-term controlled data assessing risks/bene-
fits of treatment versus control. Notwithstanding this deficiency,
long-term uncontrolled data do provide additional insight. To miti-
gate the shortcomings of data collection in the GO-REVEAL long-
term extension, efficacy data were analysed conservatively using an
ITTapproach and imputation for missing data and also considering
patients who discontinued treatment due to lack of efficacy as ACR
and DAS non-responders. Also, selected safety data such as malig-
nancies were compared with a publically available database. These
findings, although limited by the long-term extension design,
support the long-term clinical and radiographic efficacy of golimu-
mab treatment, as well as similar safety profiles between both goli-
mumab doses and other anti-TNF PsA therapies. The data also
suggest that both golimumab doses (50 and 100 mg), when admi-
nistered q4wks, have similar efficacy and safety profiles and that
increasing the dose from 50 to 100 mg q4wks adds limited benefit.
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